investing

Merck

Analysts Morgan Stanley upgraded Merck & Co. (MRK) to Overweight and raised target price to $179, citing strong cancer drug pipeline

Morgan Stanley has upgraded Merck's stock to overweight, citing confidence in its drug pipeline to sustain growth despite the impending expiration of the Keytruda patent in 2028. The firm raised its price target for Merck shares to $179, indicating a potential 17% upside.
iShares MSCI Canada ETF iShares MSCI Eurozone ETF Micron Meta Platforms Deere & Company Walmart Coinbase

Market Update: iShares MSCI Canada ETF (EWC) and European Economic Concerns Highlighted Ahead of Jobless Claims

Recent developments in the financial markets indicate potential shifts in investor sentiment, particularly regarding tariffs with Canada and economic warnings from the European Central Bank, which could influence market dynamics and sector performance.
LendingClub

Happen Inc. Transforms from Peer-to-Peer Lender to Full-Service Digital Bank with AI-Powered Lending

08/19/2026, 12:36 PM investing growth finance LendingClub
Happen, formerly known as LendingClub, has successfully transitioned from a peer-to-peer lender to a full-service digital bank, leveraging AI and a focus on high-quality borrowers to drive growth and profitability. Despite its strong fundamentals and unique business model, the company trades at a valuation discount compared to its fintech peers, suggesting potential for future appreciation.